A Swedish medical technology company
Senzime develops and markets CE-marked and FDA-approved medical technology systems, powered by unique algorithms and disposable sensors that assess the patient’s muscle function before, during and after anaesthesia.
Our vision is a world without anesthesia-related complications
CEO Statement
Growth in the first quarter was clear. Total sales growth was 64 percent, with the U.S. accounting for the largest increase, 109 percent year-over-year, and Europe up 36 percent. Sensor sales increased by 44 percent during the quarter compared to the same period in 2021.
Pia Renaudin
CEO